Details of Host Protein-DME Interaction (HOSPPI)
| General Information of Drug-Metabolizing Enzyme (DME ID: DME0620) | |||||
|---|---|---|---|---|---|
| DME Name | Serum paraoxonase/arylesterase 2 (PON2), Homo sapiens | DME Info | |||
| UniProt ID | |||||
| EC Number | EC: 3.1.1.2 (Click to Show/Hide the Complete EC Tree) | ||||
| Lineage | Species: Homo sapiens (Click to Show/Hide the Complete Species Lineage) | ||||
| Interactome | |||||
| Disease Specific Interactions between Host Protein and DME (HOSPPI) | |||||
|---|---|---|---|---|---|
| ICD Disease Classification 02 Neoplasms | |||||
| ICD-11: 2A00 Brain cancer | Click to Show/Hide the Full List of HOSPPI: 7 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Multilayered rosettes embryonal tumour | Significant hypomethylation | |||
| Interaction Name | DNMT-PON2 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypomethylation p-value: 5.22E-10; delta-beta: -5.39E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hypo-methylate the PON2 gene, which leads to a significantly increased expression of the drug-metabolizing enzyme Serum paraoxonase/arylesterase 2. As a result, the interaction between DNMT and PON2 can significantly affect the drug-metabolizing process of Serum paraoxonase/arylesterase 2. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| DNA methyltransferase (DNMT) | Diffuse midline glioma | Significant hypomethylation | |||
| Interaction Name | DNMT-PON2 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypomethylation p-value: 3.69E-16; delta-beta: -4.00E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hypo-methylate the PON2 gene, which leads to a significantly increased expression of the drug-metabolizing enzyme Serum paraoxonase/arylesterase 2. As a result, the interaction between DNMT and PON2 can significantly affect the drug-metabolizing process of Serum paraoxonase/arylesterase 2. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| DNA methyltransferase (DNMT) | Mixed neuronal-glial tumour | Significant hypomethylation | |||
| Interaction Name | DNMT-PON2 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypomethylation p-value: 7.04E-07; delta-beta: -3.85E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hypo-methylate the PON2 gene, which leads to a significantly increased expression of the drug-metabolizing enzyme Serum paraoxonase/arylesterase 2. As a result, the interaction between DNMT and PON2 can significantly affect the drug-metabolizing process of Serum paraoxonase/arylesterase 2. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| DNA methyltransferase (DNMT) | Brain neuroepithelial tumour | Significant hypomethylation | |||
| Interaction Name | DNMT-PON2 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypomethylation p-value: 2.34E-03; delta-beta: -3.50E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hypo-methylate the PON2 gene, which leads to a significantly increased expression of the drug-metabolizing enzyme Serum paraoxonase/arylesterase 2. As a result, the interaction between DNMT and PON2 can significantly affect the drug-metabolizing process of Serum paraoxonase/arylesterase 2. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| DNA methyltransferase (DNMT) | Oligodendroglial tumour | Significant hypermethylation | |||
| Interaction Name | DNMT-PON2 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypermethylation p-value: 2.45E-03; delta-beta: 3.92E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the PON2 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Serum paraoxonase/arylesterase 2. As a result, the interaction between DNMT and PON2 can significantly affect the drug-metabolizing process of Serum paraoxonase/arylesterase 2. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| DNA methyltransferase (DNMT) | Anaplastic pleomorphic xanthoastrocytoma | Moderate hypomethylation | |||
| Interaction Name | DNMT-PON2 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Moderate hypomethylation p-value: 4.06E-02; delta-beta: -2.88E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to moderatly hypo-methylate the PON2 gene, which leads to a moderatly increased expression of the drug-metabolizing enzyme Serum paraoxonase/arylesterase 2. As a result, the interaction between DNMT and PON2 can moderatly affect the drug-metabolizing process of Serum paraoxonase/arylesterase 2. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| DNA methyltransferase (DNMT) | Atypical teratoid rhabdoid tumour | Moderate hypermethylation | |||
| Interaction Name | DNMT-PON2 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Moderate hypermethylation p-value: 1.98E-04; delta-beta: 2.40E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to moderatly hyper-methylate the PON2 gene, which leads to a moderatly decreased expression of the drug-metabolizing enzyme Serum paraoxonase/arylesterase 2. As a result, the interaction between DNMT and PON2 can moderatly affect the drug-metabolizing process of Serum paraoxonase/arylesterase 2. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD Disease Classification 11 Circulatory system diseases | |||||
| ICD-11: BD51 Arterial aneurysm | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Arterial aneurysm | Significant hypermethylation | |||
| Interaction Name | DNMT-PON2 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypermethylation p-value: 1.04E-02; delta-beta: 5.70E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the PON2 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Serum paraoxonase/arylesterase 2. As a result, the interaction between DNMT and PON2 can significantly affect the drug-metabolizing process of Serum paraoxonase/arylesterase 2. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue adjacent to the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD Disease Classification 12 Respiratory system diseases | |||||
| ICD-11: CA23 Asthma | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Asthma | Significant hypermethylation | |||
| Interaction Name | DNMT-PON2 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypermethylation p-value: 1.14E-02; delta-beta: 3.27E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the PON2 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Serum paraoxonase/arylesterase 2. As a result, the interaction between DNMT and PON2 can significantly affect the drug-metabolizing process of Serum paraoxonase/arylesterase 2. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.